Scott Lee
Expertise in
6
conditions

Dr. Scott Lee

Gastroenterology
Digestive Health Center At UW Medical Center - Montlake
1959 NE Pacific St, 
Seattle, WA 
Accepting New Patients
Offers Telehealth
Expertise in
6
conditions
Digestive Health Center At UW Medical Center - Montlake
1959 NE Pacific St, 
Seattle, WA 

Overview

Scott Lee is a Gastroenterologist in Seattle, Washington. Dr. Lee is highly rated in 6 conditions, according to our data. His top areas of expertise are Crohn's Disease, Ulcerative Colitis, Viral Gastroenteritis, Endoscopy, and Colonoscopy. Dr. Lee is currently accepting new patients.

His clinical research consists of co-authoring 55 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Gastroenterology

Licenses

Internal Medicine in WA

Hospital Affiliations

University Of Washington Medical Ctr

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Coordinated Care
  • HMO
  • MANAGED MEDICAID PLAN
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Group Health Cooperative
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Lifewise

Accepted plan types not found. Please verify directly with the provider.

Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
PacificSource
  • PPO
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 18 Less Insurance Carriers -

Locations

Digestive Health Center at UW Medical Center - Montlake
1959 NE Pacific St, Seattle, WA 98195

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase 4 Study Evaluating Real-World Use of CDPATH™, a Crohn's Disease Risk Prediction Tool
A Phase 4 Study Evaluating Real-World Use of CDPATH™, a Crohn's Disease Risk Prediction Tool
Enrollment Status: Active_not_recruiting
Publish Date: November 05, 2025
Intervention Type: Other
Study Phase: Phase 4
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
Efficacy and Safety of ALTB-168 in Patients With Moderate to Severe Active, Anti-TNF Alpha and/or Anti-integrin Refractory Ulcerative Colitis: a 26-week, Open-label, Multi-center, Phase II Proof of Principle Trial
Efficacy and Safety of ALTB-168 in Patients With Moderate to Severe Active, Anti-TNF Alpha and/or Anti-integrin Refractory Ulcerative Colitis: a 26-week, Open-label, Multi-center, Phase II Proof of Principle Trial
Enrollment Status: Terminated
Publish Date: January 05, 2024
Intervention Type: Biological
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2a Study to Evaluate the Safety, Tolerability, and Early Proof of Concept of TAK-018 for the Prevention of Postoperative Crohn's Disease Recurrence
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2a Study to Evaluate the Safety, Tolerability, and Early Proof of Concept of TAK-018 for the Prevention of Postoperative Crohn's Disease Recurrence
Enrollment Status: Terminated
Publish Date: September 07, 2023
Intervention Type: Drug
Study Drug: TAK-018
Study Phase: Phase 2
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)
Enrollment Status: Completed
Publish Date: August 30, 2022
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 2
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
Certolizumab Pegol for the Treatment of Moderate to Severe Ulcerative Colitis: An Open Label Study
Certolizumab Pegol for the Treatment of Moderate to Severe Ulcerative Colitis: An Open Label Study
Enrollment Status: Completed
Publish Date: December 14, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Prospective, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Safety and Efficacy of Rifaximin for the Treatment of Moderate to Severe Crohn's Disease
A Randomized, Prospective, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Safety and Efficacy of Rifaximin for the Treatment of Moderate to Severe Crohn's Disease
Enrollment Status: Completed
Publish Date: December 09, 2021
Intervention Type: Drug
Study Drug: Rifaximin
Study Phase: Phase 2
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)
Enrollment Status: Terminated
Publish Date: June 14, 2021
Intervention Type: Other, Drug
Study Phase: Phase 3
View 11 Less Clinical Trials

55 Total Publications

Correlation of Fecal, Plasma, Serum, and Salivary Calprotectin to Endoscopic and Histologic Outcomes in Patients With Crohn's Disease: A Pilot Study.
Correlation of Fecal, Plasma, Serum, and Salivary Calprotectin to Endoscopic and Histologic Outcomes in Patients With Crohn's Disease: A Pilot Study.
Journal: Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates
Published: July 18, 2025
Similar Doctors
Shayan Irani
Expertise in
45
conditions
Dr. Shayan Irani
Gastroenterology
Expertise in
45
conditions
Dr. Shayan Irani
Gastroenterology

Virginia Mason Medical Center

1100 Ninth Avenue, 
Seattle, WA 
 (38.2 miles away)
206-624-1144
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Shayan Irani, MD, specializes in pancreaticobiliary diseases, gastrointestinal oncology, Barrett's Esophagus, gastrointestinal stenting, endoscopic mucosal resection, submucosal dissection, radio frequency ablation and other advanced therapeutic and emerging techniques.Dr. Irani enjoys spending time with his wife and daughter, the outdoors, traveling and Scuba diving. Dr. Irani is highly rated in 45 conditions, according to our data. His top areas of expertise are Cholecystitis, Gastrointestinal Fistula, Gallbladder Disease, Endoscopy, and Gastric Bypass.

Expertise in
11
conditions
Dr. Jason Dominitz
Gastroenterology
Expertise in
11
conditions
Dr. Jason Dominitz
Gastroenterology

VA Puget Sound Healthcare System

1660 S Columbian Way, 
Seattle, WA 
 (41.2 miles away)
206-764-2285
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jason Dominitz is a Gastroenterologist in Seattle, Washington. Dr. Dominitz is highly rated in 11 conditions, according to our data. His top areas of expertise are Colorectal Cancer, Juvenile Polyposis Syndrome, Peutz-Jeghers Syndrome, Colonoscopy, and Endoscopy.

Rajesh Krishnamoorthi
Expertise in
29
conditions
Dr. Rajesh Krishnamoorthi
Gastroenterology
Expertise in
29
conditions
Dr. Rajesh Krishnamoorthi
Gastroenterology

Swedish Gastroenterology - First Hill

1221 Madison Street, Suite 1220, 
Seattle, WA 
 (38.2 miles away)
206-215-4250
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

As the medical director of therapeutic Endoscopy at Swedish, I am dedicated to providing care that is both comprehensive and compassionate, uniquely tailored to your individual needs. My goal is to ensure your health journey is supported with expertise and understanding. After graduating from Madras Medical College in India, I completed my residency in Internal Medicine at Wayne State University in Detroit, where I also served as the Chief Resident in patient safety and quality (CRQS). Further honing my skills, I pursued a fellowship in Gastroenterology at the Mayo Clinic, Rochester, MN and received advanced endoscopy training at Virginia Mason Medical Center in Seattle. These experiences have equipped me with expertise in managing pancreaticobiliary disease, esophageal disorders, and early GI malignancies. In addition to my clinical practice, I am actively engaged in research and have contributed to over 50 peer-reviewed publications. As an invited reviewer for leading journals, I remain committed to staying at the forefront of medical advancements, ensuring the highest quality of care for my patients. I look forward to partnering with you in your healthcare journey. Dr. Krishnamoorthi is highly rated in 29 conditions, according to our data. His top areas of expertise are Barrett Esophagus, Bile Duct Obstruction, Cholestasis, Endoscopy, and Gastric Bypass.

Frequently Asked Questions about Dr. Scott Lee

How do I make an appointment with Dr. Scott Lee?

You can book an appointment with Dr. Scott Lee by calling their office at 206-829-4211. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Scott Lee a top-rated expert for Crohn's Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Scott Lee is classified as an Elite expert for Crohn's Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Scott Lee specialize in?

While Dr. Scott Lee is a Gastroenterology, they have specific expertise in Crohn's Disease, Ulcerative Colitis, and Viral Gastroenteritis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Scott Lee participate in research or clinical trials?

Yes. Dr. Scott Lee has published 55 articles and abstracts on conditions like Crohn's Disease. You can view a list of Dr. Scott Lee's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Scott Lee accept my insurance?

Dr. Scott Lee accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 206-829-4211 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lee's expertise for a condition
ConditionClose
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile